Please use this identifier to cite or link to this item: https://swslhd.intersearch.com.au/swslhdjspui/handle/1/13035
Full metadata record
DC FieldValueLanguage
dc.contributor.authorConnor, S.-
dc.contributor.authorWu, Y. C.-
dc.date.accessioned2024-09-02T05:57:27Z-
dc.date.available2024-09-02T05:57:27Z-
dc.date.issued2024-
dc.identifier.issn978-104013849-6 (ISBN); 978-163091650-3 (ISBN)-
dc.identifier.urihttps://swslhd.intersearch.com.au/swslhdjspui/handle/1/13035-
dc.description.abstractThe range of biologic therapies currently available for treating inflammatory bowel disease (IBD) include anti-tumor necrosis factor (anti-TNF) agents, infliximab, adalimumab, certolizumab, and golimumab; one anti-adhesion molecule, vedolizumab; and one interleukin (IL) 12/IL-23 antagonist, ustekinumab. The foundation of selecting the optimal treatment for a patient with IBD rests in individualized assessment of a patient?s risk-to-benefit ratio. � 2022 by Taylor & Francis Group.-
dc.publisherCRC Press-
dc.titleWHAT ARE THE RISKS OF BIOLOGIC THERAPIES AND HOW DO YOU COMMUNICATE THEM TO PATIENTS?-
dc.typeBook Section-
dc.description.affiliatesDepartment of Gastroenterology and Hepatology, Liverpool Hospital, South Western Sydney Clinical School, University of New South Wales, Sydney, NSW, Australia Ingham Institute of Applied Medical Research, Liverpool, NSW, Australia South Western Sydney Clinical School, University of New South Wales, Sydney, NSW, Australia-
dc.identifier.doi10.1201/9781003523567-23-
dc.identifier.journaltitleCurbside Consultation in IBD: 49 Clinical Questions-
Appears in Collections:Liverpool Hospital

Files in This Item:
There are no files associated with this item.


Items in Prosentient are protected by copyright, with all rights reserved, unless otherwise indicated.

Google Media

Google ScholarTM

Who's citing